According to National Kidney Foundation, people hospitalized with COVID-19 are at significant risk of (acute kidney injury) AKI, which can lead to serious illness, dialysis, and even death. The recovered COVID-19 patients who had an AKI or (acute renal failure) ARF are recommended to be seen regularly by a kidney doctor because their risk of developing chronic kidney disease is higher than others.
COVID-19 patients who did not develop an AKI, but who had blood and/or protein in their urine, should be monitored since they are at increased risk of developing chronic- and end-stage kidney disease. With the COVID-19 pandemic, in addition to the development of vaccines and therapeutic drugs, there is a growing call for the development of more precise and simple testing technologies and the expansion of testing structures. COVID-19 has also impacted the regulatory environment and practices, as governments and healthcare providers face unprecedented challenges. Regulatory authorities utilized methods to speed approval of diagnostic products.
Companies have taken strategic developments to introduce COVID-19 rapid tests, sustain their revenues, and nullify the impact of COVID-19 on their operational capabilities.
The rising geriatric population in developed and developing regions will positively influence the growth of the urinalysis market. Due to rapid growth in the senior population, the prevalence of age-associated diseases such as diabetes, liver, and kidney diseases is expected to increase significantly.
For More Information Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153479294
Moreover, as markets in the US and Europe are maturing, most players are shifting their focus to emerging markets. The high investments in healthcare and life sciences research in emerging markets play an essential role in upgrading laboratory infrastructure in these countries. This, in turn, supports the installation of diagnostic systems in laboratories and leads to the growth of the urinalysis market.
In particular, the markets in developing countries, which are price-sensitive, prefer instruments that are cheap and offer similar functionalities. In the absence of well-grounded regulatory frameworks, there may be an influx of low-quality and refurbished products into the economy.
Considering these factors, the demand for refurbished analyzers can be expected to increase in the coming years, as these systems offer the same functionalities at a lower cost. This is expected to hamper the revenue of companies offering branded analyzers, and thus restraining the overall growth of the market.
The urinalysis market is segmented into disease screening and pregnancy and fertility. In 2020, the disease screening segment accounted for the largest share. This can be attributed to the increasing incidence of UTIs, diabetes, liver diseases and kidney ailments worldwide.
Some key players in the urinalysis market (2021- 2026)
Siemens Healthineers AG (Germany)
Roche Diagnostics Ltd. (Switzerland)
Cardinal Health Inc. (US)
Abbott Laboratories (US)
Danaher Corporation (US)
The large share of this region can be attributed to the growing geriatric population, implementation of favorable government initiatives, increasing healthcare expenditure, improved healthcare infrastructure, and the availability of technologically advanced instruments.